Posted by Michael Wonder on 16 Aug 2021
Merck Canada initiates rolling submission to Health Canada for molnupiravir, an investigational oral therapeutic agent for the treatment of COVID-19
13 August 2021 - Merck today announced the initiation of a rolling submission to Health Canada for molnupiravir, an investigational twice daily oral anti-viral agent currently in trials as a potential treatment for COVID-19.
Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics.
